CureMatch
×
  • Physicians
  • Patients
  • Employers
  • About Us
  • News
    • CureMatch News
    • Validation and Research
    • Events & Conferences
  • Contact
  • Login
David Szekeres

David Szekeres

BOARD DIRECTOR, LIFE SCIENCES EXECUTIVE

David Szekeres is a seasoned executive with over 20 years in the life sciences industry, with deep operational, commercial, corporate development, strategy, financial, investor relations, and legal experience. Mr. Szekeres has extensive experience in developing and executing biotechnology growth strategies with expertise in corporate strategy, mergers, and acquisitions, partnering on more than $30 billion in biotechnology transactions, and raising more than $2 billion for various companies in the biotechnology sector.

Mr. Szekeres currently serves as Executive Vice President and Chief Operating Officer of Heron Therapeutics, a commercial-stage biotechnology company focused on developing novel, patient-focused solutions that apply innovative science and technologies for patients suffering from cancer and pain. He is also a member of the Board of Trustees of the Sanford Burnham Prebys Medical Discovery Institute, and Chairman of the Board of Directors at Animantis, a software company focused on artificial intelligence applications to improve drug discovery and development.

Previously, Mr. Szekeres was the Chief Financial Officer, Chief Business Officer, and General Counsel at Regulus Therapeutics. Prior to Regulus Therapeutics, Mr. Szekeres was the Head of Mergers and Acquisitions at Life Technologies Corporation through its acquisition by Thermo Fisher Scientific for $16 billion.

Mr. Szekeres received his Juris Doctor degree from Duke University School of Law, and his Bachelor of Administration degree from University of California, Irvine.

logo

+1 (858) 284-0488

FAX: +1 (858) 430-5813

Quick Links

  • Physicians
  • About CureMatch
  • News and Latest Posts
    • CureMatch News
    • Validation and Case Studies
    • Events and Conferences
  • Contact Us
  • FAQ

Latest News and Results

  • Interview with Dr. Razelle Kurzrock of CureMatch: Why Patients Need Precision Cancer Medicine Apr 6

    In this dynamic interview, Chief Medical Advisor, Dr. Kurzrock, sits down with Michelle Morand, Co-Founder...

  • New Study Validates Payer/Physician Use of AI to Cut Wasteful Spending on High-Cost, Low-Value Cancer Drugs Mar 28

    The Research Consortium announced the release of a new study today that challenges common misconceptions...

  • CureMatch Names Life Sciences Executive David Szekeres as Board Director Feb 22

    CureMatch, Inc., a healthcare technology company that leverages artificial intelligence (AI) to power precision medicine...

© 2021 CureMatch, Inc. CureMatch is a registered trademark.
Terms of Use | Privacy Policy | HIPAA Notice

We’d like to send you a CureMatch Sample Analysis

 

Sample Analysis Download Form

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data